Retrospective analysis of treatment outcomes in 70 patients with t(8;21) acute myeloid leukemia
-
- NUMATA Ayumi
- Department of Hematology, Kanagawa Cancer Center
-
- FUJIMAKI Katsumichi
- Department of Hematology/Immunology, Fujisawa City Hospital
-
- AOSHIMA Tomohiro
- Department of Hematology, Yamato Municipal Hospital
-
- ONIZUKA Makoto
- Department of Hematology, Tokai University School of Medicine
-
- HAGIHARA Maki
- Department of Hematology, Kanagawa Cancer Center
-
- MIYAZAKI Koji
- Department of Hematology, Kitasato University Hospital
-
- FUJITA Hiroyuki
- Department of Rheumatology/Hematology/Infectious Disease, Yokohama City University Hospital
-
- SAKAI Rika
- Department of Hematology, Yokohama City University Medical Center
-
- MACHIDA Shinichiro
- Department of Hematology, Tokai University School of Medicine Department of Hematology, Japanese Red Cross Hadano Hospital
-
- TANAKA Eri
- Department of Hematology, Shonan Kamakura General Hospital
-
- NAKAJIMA Yuki
- Department of Hematology, Yokosuka City Hospital
-
- HATTORI Yukako
- Department of Hematology, Shizuoka Red Cross Hospital
-
- TANAKA Masatsugu
- Department of Hematology, Kanagawa Cancer Center
-
- YAMAZAKI Etsuko
- Department of Hematology, Yamato Municipal Hospital
-
- SHIRASUGI Yukari
- Department of Hematology, Tokai University School of Medicine
-
- INOUE Yasuyuki
- Department of Hematology, St.Marianna University School of Medicine Hospital
-
- WATANABE Shigeki
- Department of Hematology, Ebina General Hospital
-
- FUJISAWA Shin
- Department of Hematology, Yokohama City University Medical Center
Bibliographic Information
- Other Title
-
- t(8;21)を有する急性骨髄性白血病70例の治療成績
- 臨床研究 t(8;21)を有する急性骨髄性白血病70例の治療成績
- リンショウ ケンキュウ t(8;21)オ ユウスル キュウセイ コツズイセイ ハッケツビョウ 70レイ ノ チリョウ セイセキ
Search this article
Abstract
We conducted a retrospective study to evaluate outcomes and prognostic factors of newly diagnosed patients with t(8;21) acute myeloid leukemia (AML). There were 70 patients (43 men and 27 women) with a median age of 48 years old (range, 17∼76 years old). Sixty-five patients achieved complete remission (CR) after induction chemotherapy. Fifty-seven patients received consolidation chemotherapy based on the policy of not performing allogeneic hematopoietic stem cell transplantation (allo-HSCT) at the time of first CR. Twenty-seven of the 57 patients relapsed (relapse rate, 47%). The median time from the achievement of the first CR to relapse was 307 days (96∼1,256 days). A white blood cell count of more than 25,400/μl at diagnosis was associated with a higher relapse rate than a white blood cell count of less than or equal to 25,400/μl (75% vs. 43%, P=0.04). Nineteen of the 25 relapsed patients who received re-induction therapy experienced a second CR (second CR rate, 76%). Twenty-six patients (5 with first CR, 12 with second CR, and 9 without remission) received allo-HSCT. The five-year overall survival and disease-free survival rates were 61% and 45%, respectively. Patients with t(8;21) AML had a high CR rate, but about half of them relapsed. However, this report could not show prognostic factors for the identification of patients who should receive allo-HSCT at the time of their first CR.
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 53 (7), 698-704, 2012
The Japanese Society of Hematology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001205034546560
-
- NII Article ID
- 130004501707
- 10030990325
- 40019395893
-
- NII Book ID
- AN00252940
-
- COI
- 1:STN:280:DC%2BC38bmslGjsA%3D%3D
-
- ISSN
- 18820824
- 04851439
-
- NDL BIB ID
- 023908354
-
- PubMed
- 22975772
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed